The clinical study of NO-mediated Vascular Function in Covid-19 Patient begins in Italy
Photo by Kate Trifo
Italian Istituti Clinici Scientifici Maugeri SpA is conducting the clinical trial NO-mediated Vascular Function in Covid-19 Patient.
The 2019 coronavirus-induced infection (COVID-19) has caused a pandemic that has spread worldwide. Up to date, many subjects affected by the virus report important sequelae on different organs increasing morbidity and exacerbating previous pathological conditions. Mortality is also increased in cases of comorbidities such as cardiovascular disease, hypertension and diabetes. COVID-19 infection is caused by Coronavirus-2 (SARS-CoV-2). Concerning the specific interaction of SARS-CoV-2 with the cardiovascular system, we know that this virus enters the body through the receptors for the conversion of angiotensin II (ACE2r) that are present in the lungs, heart, intestinal epithelium and vascular endothelium. This receptor's availability suggests a multi-organ involvement with a consequent multi-organ dysfunction, as found in patients affected by SARS-CoV-2 infection.
The main aim of this project will be to investigate the peripheral NO-mediated vascular function in the leg of patients recovering from Covid-19 pneumonia.
Actual study start date is May 30, 2020. The researchers expect to complete the study by December 2020.
Leg Blood Flow is the primary outcome measure.
Among study population are patients, from acute care hospitals, diagnosed with COVID-19 pneumonia, with documented positive throat swab, within one month from discharge.
Patients with previous cardiovascular, respiratory, neurological or orthopaedic diseases are excluded from participation.
The location of the study is as follows (further details can be found here https://ichgcp.net/clinical-trials-registry/NCT04625036) ICS Maugeri IRCCS, U.O. Emergenza Coronavirus di Lumezzane, Lumezzane, Brescia, Italy, 25065.
